• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
CDC awards Truveta a real-world data contract to study COVID, maternal health, and pediatric care

CDC awards Truveta a real-world data contract to study COVID, maternal health, and pediatric care

by Ellie Lampton | Jan 22, 2024

BELLEVUE, Wash. – January 22, 2024 – Today, Truveta, a growing collective of 30 health systems with a shared mission of Saving Lives with Data, was awarded a contract with the U.S. Centers for Disease Control and Prevention (CDC) for privacy-preserving record linkage...
Truveta Research on increased speech delays in children during the pandemic published in JAMA Pediatrics

Truveta Research on increased speech delays in children during the pandemic published in JAMA Pediatrics

by Ellie Lampton | Dec 5, 2023

In a study of more than 2.4 million children under the age of 5, new research shows a significant increase in the rate of first-time speech delay diagnoses after July 2020. BELLEVUE, Wash. – December 5, 2023 – Today Truveta announced new research published in JAMA...

Truveta welcomes Patrick Caubel, Pfizer Chief Safety Officer, to its Board of Directors

by Ellie Lampton | Dec 4, 2023

BELLEVUE, Wash. – December 4, 2023 – Truveta, the company with a mission of saving lives with data, welcomes its first member from the life science industry to its Board of Directors. The Truveta Board of Directors ensures the data and analytics company is operating...
Largest real-world data study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

Largest real-world data study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

by Ellie Lampton | Nov 27, 2023

In the first comparative effectiveness study of tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss using real-world data, Truveta Research found that patients with overweight or obesity taking tirzepatide were three times more likely to achieve 15%...
Truveta announces availability of millions of echocardiogram reports to advance cardiovascular research

Truveta announces availability of millions of echocardiogram reports to advance cardiovascular research

by Ellie Lampton | Nov 8, 2023

With more than 56.6 million clinical observations from more than 2.7 million echocardiogram reports and growing, Truveta is the market leader in real-world data for cardiovascular research. BELLEVUE, Wash. – November 8, 2023 – Today Truveta announced the availability...
« Older Entries
Next Entries »

Share this


Recent posts

  • ISPOR 2025: Trends in the prescribing and dispensing of GLP-1 anti-obesity medications among adults with cardiovascular disease
  • ISPOR 2025: Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation 
  • ISPOR 2025: Characteristics and adherence of patients initiating injectable cabotegravir for HIV treatment or prevention 

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Get started

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Interested in learning more?

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice